SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934

Endovasc Ltd., Inc.
(Name of Registrant as Specified in Its Charter)
________________________
(Name of Person(S) Filing Proxy Statement, if Other Than the Registrant)

Payment of filing fee: (check the appropriate box):
|X| No fee required.
| | Fee computed on table below per Exchange Act Rule 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies: ___
(2) Aggregate number of securities to which transaction applies: ___
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined): ___
(4) Proposed maximum aggregate value of transaction: ___
(5) Total fee paid: ___
| | Fee paid previously with preliminary materials: ___
| | Check box if any part of the fee is offset as provided by Exchange Act Rule
0-1(a)(2) and identify the filing for which the offsetting fee was paid
previously, identify the previous filing by registration statement number, or
the form or schedule and the date its filing.
(1) Amount Previously Paid: ___
(2) Form, Schedule or Registration Statement No.: ___
(3) Filing Party: ___
(4) Date Filed: ___

ENDOVASC LTD., INC.
15001 WALDEN ROAD, SUITE 108
MONTGOMERY, TEXAS 77356

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 18, 2002

The Annual Meeting of Stockholders (the "Annual Meeting") of Endovasc Ltd.,
Inc., (the "Company") will be held at Del Lago Hotel, 600 Del Lago Blvd.,
Montgomery, Texas 77356, on November 18, 2002 at 2:00 PM (CST) for the following
purposes:

(1) To elect three (3) directors.

(2) To ratify the selection of Ham, Langston and Brezina, L.L.P. as the
Company's independent auditor for the fiscal year ending June 30, 2003.

(3) To act upon such other business as may properly come before the Annual
Meeting.

Only holders of common stock of record at the close of business on October
15, 2002 will be entitled to vote at the Annual Meeting or any adjournment
thereof.

You are cordially invited to attend the Annual Meeting. Whether or not you
plan to attend the Annual Meeting, please sign, date and return your proxy to us
promptly. Your cooperation in signing and returning the proxy will help avoid
further solicitation expense.

BY ORDER OF THE BOARD OF DIRECTORS

/S/ GARY R BALL
DIRECTOR AND SECRETARY

OCTOBER 18, 2002
MONTGOMERY, TEXAS

================================================================================
IMPORTANT

WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, PLEASE SIGN AND RETURN THE
ENCLOSED ENVELOPE. IF A QUORUM IS NOT REACHED, THE COMPANY WILL HAVE THE ADDED
EXPENSE OF RE-ISSUING THESE PROXY MATERIALS. IF YOU ATTEND THE MEETING AND SO
DESIRE, YOU MAYWITHDRAW YOU PROXY AND VOTE IN PERSON.

THANK YOU FOR ACTING PROMPTLY

================================================================================

ENDOVASC LTD., INC.
15001 WALDEN ROAD, SUITE 108
MONTGOMERY, TEXAS 77356

PROXY STATEMENT
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 18, 2002

This proxy statement (the "Proxy Statement") is being furnished to
stockholders (the Stockholders") in connection with the solicitation of proxies
by the Board of Directors of Endovasc Ltd., Inc., a Delaware corporation (the
"Company") for their use at the Annual Meeting (the "Annual Meeting") of
Stockholders of the Company to be held at Del Lago Hotel, 600 Del Lago Blvd.,
Montgomery, Texas 77356, on November 18, 2002 at 2:00 PM (CST), and at any
adjournments thereof, for the purpose of considering and voting upon the matters
set forth in the accompanying Notice of Annual Meeting of Stockholders (the
"Notice"). This Proxy Statement and the accompanying form of proxy (the "Proxy")
are first being mailed to Stockholders on or about October 18, 2002. The cost
of solicitation of proxies is being borne by the Company.

The close of business on October 15, 2002 has been fixed as the record date
for the determination of Stockholders entitled to notice of and to vote at the
Annual Meeting and any adjournment thereof. As of record date, there were
approximately 34,000,000 shares of the Company's common stock, par value $0.001
per share (the "Common Stock"), issued and outstanding. The presence, in person
or by proxy, of a majority of the outstanding shares of Common Stock on the
record date is necessary to constitute a quorum at the Annual Meeting. Each
share is entitled to one vote on all issues requiring a Stockholder vote at the
Annual Meeting. Each nominee for Director named in Proposal Number 1 must
receive a majority of the votes cast in person or by proxy in order to be
elected. Stockholders may not cumulate their votes for the election of
Directors. The affirmative vote of a majority of the shares of Common Stock
present or represented by proxy and entitled to vote at the Annual Meeting is
required for the ratification of Number 2 set forth in the accompanying Notice.

All shares represented by properly executed proxies, unless such proxies
previously have been revoked, will be voted at the Annual Meeting in accordance
with the directions on the proxies. If no direction is indicated, the shares
will be voted (I) FOR THE ELECTION OF THE NOMINEES NAMED HEREIN, AND (II) FOR
THE RATIFICATION OF HAM, LANGSTON AND BREZINA, L.L.P. AS THE COMPANY'S
INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING JUNE 30, 2003. The Board of
Directors is not aware of any other matters to be presented for action at the
Annual Meeting. However, if any other matter is properly presented at the Annual
Meeting, it is the intention of the persons named in the enclosed proxy to vote
in accordance with their best judgment on such matters.

The enclosed Proxy, even though executed and returned, may be revoked at
any time prior to the voting of the Proxy (a) by execution and submission of a
revised proxy, (b) by written notice to the Secretary of the Company, or (c) by
voting in person at the Annual Meeting.

- --------------------------------------------------------------------------------

(1) TO ELECT THREE (3) DIRECTORS FOR THE ENSUING YEAR

- --------------------------------------------------------------------------------

NOMINEES FOR DIRECTORS

The persons named in the enclosed Proxy have been selected by the Board of
Directors to serve as proxies (the "Proxies") and will vote the shares
represented by valid proxies at the Annual Meeting of Stockholders and
adjournments thereof. They have indicated that, unless otherwise specified in
the Proxy, they intend to elect as Directors the nominees listed below. Each
duly elected Director will hold office until his successor shall have been
elected and qualified.

Unless otherwise instructed or unless authority to vote is withheld, the
enclosed Proxy will be voted for the election of the nominees listed below.
Although the Board of Directors of the Company does not contemplate that any of
the nominees will be unable to serve, if such a situation arises prior to the
Annual Meeting, the persons named in the enclosed Proxy will vote for the
election of such other person(s) as may be nominated by the Board of Directors.

The Board of Directors unanimously recommends a vote FOR the election of
each of the nominees listed below. All of the nominees are presently our
directors.

Dr. David P. Summers, age 62, serves as our Chief Executive Officer and
Chairman. Dr. Summers has served in this capacity on a full-time basis since our
inception and is primarily responsible for our operations as a whole. Prior to
working with Endovasc, Dr. Summers founded American BioMed, Inc. and served as
its President and Chief Executive Officer from 1984 to 1995. Dr. Summers is a
Fellow in the American College of Angiology, a Fellow in the International
Society for endovascular Surgery, as well as the inventor of several medical
devices used to treat cardiovascular diseases. He is the author of 25 issued
patents and has 8 patents pending. Prior to founding American BioMed, Dr.
Summers assisted with the management of several corporations, including C.R.
Bard, Inc., a manufacture and distributor of cardiovascular medical products,
Karl Stortz Endoscopy, an endoscopic instrument company, and Pall Corporation, a
manufacturer and distributor of blood filtration products. Dr. Summers holds an
M.B.A. degree from Pepperdine University as well as a Ph.D. in International
Economics from Kennedy-Western University. He is also a member of the New York
Academy of Sciences, the American Association of Advancement of Science, the
Houston Inventors Association, the European Vascular Society and the Society of
Plastic Engineers. Dr. Summers is the father-in-law of Gary Ball.

M. Dwight Cantrell, age 56, serves as our Chief Financial Officer,
Treasurer and Director. Mr. Cantrell has maintained, and continues to maintain,
a public accounting practice in the state of Texas since 1976. Mr. Cantrell is a
public accountant. He has an extensive background in the banking and venture
capital markets and a member of the Association of Biotech Financial Officers.
He has served as CFO since 1997.

Gary R. Ball, age 42, serves as our Secretary, Director and is one of our
co-founders. Prior to co-founding us in July 1996, Mr. Ball served as a
mechanical engineer with American BioMed, Inc., from 1991 to 1996. Mr. Ball is a
co-inventor of two U.S. patents and is experienced in prototype design,
research, and development, as well as reliability testing and patent research
and filing. Mr. Ball is the son-in-law of Dr. Summers.

Our Directors are elected annually and hold office until the next annual
meeting of our stockholders or until their successors are elected and qualified.
Officers are elected annually and serve at the discretion of the Board of
Directors. Other than noted above, there is no family relationship between or
among any of our directors and executive officers. Our Board of Directors
consists of three persons.

Non-employee Directors receive no salary for their services and receive no
fee from the Company for their participation in meetings, although all Directors
are reimbursed for reasonable travel and other out-of-pocket expenses incurred
in attending meetings of the Board.

OUR DIRECTORS AND OFFICERS

Name Age Title
- ---- --- -----

David P. Summers 63 Chief Executive Officer
and Chairman (1996 to present)

Diane Dottavio 50 Director of Research and Development
(since March 2000 to present)

M. Dwight Cantrell 56 Chief Financial Officer, Treasurer and Director
(January 1997 to present)

Gary R. Ball 42 Secretary and Director (July 1996 to present)

Diane Dottavio, age 50, serves as our Director of Research and Development.
Prior to joining us in March of this year, Ms. Dottavio served as Senior
Scientist with Leukosite, Inc., from 1994 to 1996, and as Director of Laboratory
Instruction and Research at the University of Houston, from 1997 to this year.
Ms. Dottavio holds a B.S. in Biology and a M.S. in Organic Chemistry from the
University of New Mexico, as well as a Ph.D. in Biochemistry from the University
of Texas.

RELATED TRANSACTIONS

As of the June 30, 2002, we have not entered into a transaction during the
past two years with a value in excess of $60,000 with a Director, officer, or
beneficial owner of 5% or more of our capital stock, or members of their
immediate families that had, or is to have, a direct or indirect material
interest in us, except as follows:

During the fiscal year ended June 30, 1998, we also entered into an
agreement with M. Dwight Cantrell under the terms of which he was compensated
for past services as our Director. Under the terms of this agreement, Mr.
Cantrell was granted an option to purchase 100,000 shares of our common stock at
a purchase price of $0.25 per share for a term of three years. This option was
exercised during the fiscal year ended June 30, 2002.

During the fiscal year ending June 30, 1998, we entered into a stock option
agreement with Dr. David P. Summers. Under this agreement, Dr. Summers was
granted an option to purchase up to 1,000,000 shares of our common stock at a
purchase price of $0.25 per share exercisable for a period of three years. This
option was exercised during the fiscal year ending June 30, 2001.

During the year ended June 30, 2002, certain officers of the Company
transferred 3,100,000 shares of their common stock back to the Company in the
form of a note payable to stockholders to provide the Company enough common
shares to meet its preferred stock conversion requirements. Subsequently and due
to the decrease in the market price per share of the Company's common stock,
6,850,000 shares of common stock were issued to these stockholders as repayment
of these notes payable to the stockholders. All transactions were recorded by
the Company based on the fair market value of the stock, which resulted in no
effect to the statement of operations.

During the year ended June 30, 2002, Dr. Summers advanced an additional
$324,000 to the Company in the form of a note payable to stockholder and
received 5,800,000 shares of common stock as repayment of $365,000 of this note
payable to stockholder. The balance of this note of $58,000 as of June 30, 2002
is due on demand, non-interest bearing and is not collateralized.

As of June 30, 2002, certain officers and directors of the Company
exchanged 17,779,083 shares of their common stock for 1,777,908 shares of Series
B convertible preferred stock, which included preferential voting rights of 500
times those attributable to common stockholders. The right to convert common
stock to Series B convertible preferred stock was offered only to certain common
stockholders, including officers and directors of the Company. Such
stockholders, officers and directors, who were selectively and preferentially
offered Series B convertible preferred stock, avoided a 97.5% dilution of their
position as common stockholders that all other common stockholders experienced.
Effective July 9, 2002, upon reincorporation of the Company in the state of
Delaware, and subsequent to the 40 to 1 reverse split of common stock, the
officers' and directors' Series B preferred stock was automatically converted
back to 17,779,083 shares of the Company's common stock.

The Company believes that all transactions between the Company and its
officers, directors and employees described above are on terms no less favorable
to the Company than could have been obtained from unaffiliated parties under
similar circumstances other than certain advances received from Dr. David
Summers which are non-interest bearing.

Other than as set forth above, we know of no other transactions that couldresult
in a change of control of us.

INFORMATION CONCERNING THE BOARD OF DIRECTORS AND ITS COMMITTEES

We have no compensation committee and no nominating committee. Decisions
concerning executive officer compensation for 2002 were made by the full Board
of Directors. David P. Summers, M. Dwight Cantrell and Gary R. Ball are the
only directors of the Company who are also officers of the Company. We no Audit
Committee. The Board of Directors held 11 meetings during the fiscal year
ended June 30, 2002. All of our Directors attended at least 75% of our Board
meetings. There is no family relationship between or among any of the directors
and executive officers of the Company.

COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934

The Company believes all persons so required, have complied with Section
16(a) of the Securities Exchange Act of 1934 with respect to the fiscal year
2002.

EXECUTIVE COMPENSATION

The following table sets forth certain summary information with respect to
the compensation paid to the executive officers for services rendered to us, in
all capacities, for the fiscal years ended June 30, 2001, 2000, 1999, 1998, and
1997. Other than as listed below, we had no executive officers whose total
annual salary and bonus exceeded $100,000 for that fiscal year:

Summary Compensation Table

Long Term Compensation
Annual Compensation Awards Payouts

Other Securities
Annual Restricted Under- Other
Name and Compen- Stock Lying LTIP Compen-
Principal Salary Bonus sation Awards Options/ Payouts sation
Position Year ($) ($) ($) ($) SARs(#) ($) ($)

David P. Summers 2002 78,712 - - - - - -
CEO and Director 2001 75,097 - - - 200,000 $ 0.40
2000 66,500 - - - - - -

Dr. Summers exercised no options during fiscal year ending June 2002 During this
same period Dr. Summers Owned no options, other than those noted in the table
above.

Employment and Other Agreements

We have entered into an employment agreement with Dr. David Summers. We
entered into a three-year employment contract with Dr. Summers in 1996,
providing for annual compensation of $150,000 in cash and equity interests. The
original term of this contract has expired, but the term has been renewed
annually for a one-year period in June of each year since its original
expiration.

Stock Option Plans

In May 2002, the Company adopted the 2002 Directors, Officers and
Consultants Stock Option, Stock Warrant and Stock Award Plan (the "Plan"). The
purpose of the Plan is to maintain the ability of Endovasc Ltd., Inc. to attract
and retain highly qualified and experienced directors, employees and consultants
and to give such directors, employees and consultants a continued proprietary
interest in the success of the Company. In addition, the Plan is intended to
encourage ownership of common stock of the Company by the directors, employees
and consultants of the Company and to provide increased incentive for such
persons to render services and to exert maximum effort for the success of the
Company's business. Subject to adjustment so that the total number of shares
issuable under the Plan will equal 15% of the total number of issued and
outstanding common stock of the Company, the aggregate number of shares of
common stock that may be optioned, subject to conversion or issued under the
Plan is 18,750,000 which has not been adjusted for the 40 to 1 reverse split of
the Company's common stock.

The maximum term of options granted under this Plan is ten years. The
aggregate fair market value of the stock with respect to which incentive stock
options are first exercisable in any calendar year may not exceed $1,000,000.
The exercise price of incentive stock options must be equal or greater than the
fair market value of common stock on the date of grant. The exercise price of
incentive stock options granted to any person who at the time of grant owns
stock possessing more than 10% of the total combined voting power of all classes
of stock must be at least 110% of the fair market value of such stock on the
date of grant, and the term of these options cannot exceed five years.

Non-qualified stock options or warrants, restricted common stock and/or
convertible preferred stock may be granted under the Plan. The terms of these
issuances are determined based on the sole discretion of the Company's
Compensation Committee.

SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information as of October 15, 2002
with respect to the number of shares of each class of voting stock beneficially
owned by (i) those persons known to the Company to be the owners of more than
five percent of any such class of voting stock of the Company, (ii) each
director of the Company and (iii) all directors and executive officers of the
Company as a group. Unless otherwise indicated, each of the listed persons has
sole voting and investment power with respect to the shares beneficially owned
by such shareholder.

Common Stock

Name and Address Amount of Class of Percent of
Common Stock Class Owned
Benefically Owned
(2) (3)

David P. Summers 10,985,000 33.44%
Diane Dottavio 694,120 2.11%
M. Dwight Cantrell 3,431,880 10.45%
Gary R. Ball 1,388,000 4.23%

All Directors and Executive
Officers as a Group 16,499,670 50.23%

(1) Except as otherwise noted, the address of the beneficial owners described
in this table shall be c/o Endovasc Ltd., Inc., 15001 Walden Road, Suite
108, Montgomery, Texas 77356.

(2) The securities "beneficially owned" by a person are determined in
accordance with the definition of "beneficial ownership" set forth in the
rules and regulations promulgated under the Securities Exchange Act of
1934, as amended, and accordingly, may include securities owned by and for,
among others, the spouse and/or minor children of an individual and any
other relative who has the same home as such individual, as well as other
securities as to which the individual has or shares voting or investment
power or which such person has the right to acquire within 60 days after
the Record Date pursuant to the conversion of convertible equity, exercise
of options, or otherwise. Beneficial ownership may be disclaimed as to
certain of the securities.

- --------------------------------------------------------------------------------
(2) TO RATIFY THE SELECTION OF HAM, LANGSTON AND BREZINA, L.L.P. THE
COMPANY'S INDEPENDENT AUDITOR FOR
THE FISCAL YEAR ENDING JUNE 30, 2003
- --------------------------------------------------------------------------------

The Board of Directors has selected Ham, Langston and Brezina, L.L.P. as
the Company's independent auditor for the current fiscal year. Although not
required by law or otherwise, the selection is being submitted to the
Stockholders of the Company as a matter of corporate policy for their approval.
The Board of Directors wishes to obtain from the Stockholders a ratification of
their action in appointing their existing certified public accountant, Ham,
Langston and Brezina, L.L.P., independent auditor of the Company for the fiscal
year ending June 30, 2003. Such ratification requires the affirmative vote of a
majority of the shares of Common Stock present or represented by proxy and
entitled to vote at the Annual Meeting.

In the event the appointment of Ham, Langston and Brezina, L.L.P. as
independent auditor is not ratified by the Stockholders, the adverse vote will
be considered as a direction to the Board of Directors to select other
independent auditors for the fiscal year ending June 30, 2003. A representative
of Ham, Langston and Brezina, L.L.P. is expected to be present at the Annual
Meeting with the opportunity to make a statement if he so desires and to respond
to appropriate questions. The Board of Directors unanimously recommends a vote
FOR the ratification of Ham, Langston and Brezina, L.L.P. as independent auditor
for fiscal year ending June 30, 2003.

AUDIT FEES

Ham, Langston and Brezina, L.L.P. billed us in the aggregate amount of
$33,000 for professional services rendered for their audit of our annual
financial statements and their reviews of the financial statements included in
our Forms 10-QSB for fiscal 2002. We were not billed for professional services
from any other accounting firm for audits or reviews done in fiscal 2002.

FINANCIAL INFORMATION SYSTEMS DESIGN AND IMPLEMENTATION FEES

In fiscal 2002, Ham, Langston and Brezina, L.L.P. did not bill us for, nor
perform, any financial information systems design or implementation. In fiscal
2002, we were not billed for professional services from any other accounting
firm for information systems design or implementation.

ALL OTHER FEES

We were not billed for any other professional services by any other
accounting firm in fiscal 2002.

AUDITOR INDEPENDENCE

Our Audit Committee considers that the work done for us in fiscal 2002 by
Ham, Langston and Brezina, L.L.P. is compatible with maintaining Ham, Langston
and Brezina, L.L.P.'s independence.

AUDITOR'S TIME ON TASK

At least 50% of the work expended by Ham, Langston and Brezina, L.L.P. on
our fiscal 2002 audit was attributed to work performed by Ham, Langston and
Brezina, L.L.P.'s full-time, permanent employees.

- --------------------------------------------------------------------------------
(3) OTHER MATTERS
- --------------------------------------------------------------------------------

The Board of Directors is not aware of any other matters to be presented
for action at the Annual Meeting. However, if any other matter is properly
presented at the Annual Meeting, it is the intention of the persons named in the
enclosed proxy to vote in accordance with their best judgment on such matters.

FUTURE PROPOSALS OF STOCKHOLDERS

The deadline for stockholders to submit proposals to be considered for
inclusion in the Proxy Statement for the 2003 Annual Meeting of Stockholders is
March 31, 2003.

BY ORDER OF THE BOARD OF DIRECTORS

/S/ GARY R. BALL
DIRECTOR AND SECRETARY

OCTOBER 18, 2002
MONTGOMERY, TEXAS

PROXY
ENDOVASC LTD., INC.
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS FOR THE ANNUAL
MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 18, 2002.

The undersigned hereby appoints David P. Summers and M. Dwight Cantrell,
and each of them as the true and lawful attorneys, agents and proxies of the
undersigned, with full power of substitution, to represent and to vote all
shares of Common Stock of Endovasc Ltd., Inc. held of record by the undersigned
on October 15, 2002, at the Annual Meeting of Stockholders to be held on
November 18, 2002 at 2:00 PM (CST) at the Del Lago Conference Center, 600 Del
Lago Blvd., Montgomery, Texas 77356, and at any adjournments thereof. Any and
all proxies heretofore given are hereby revoked.

WHEN PROPERLY EXECUTED, THIS PROXY WILL BE VOTED AS DESIGNATED BY THE
UNDERSIGNED. IF NO CHOICE IS SPECIFIED, THE PROXY WILL BE VOTED FOR THE
NOMINEES LISTED IN NUMBER 1 AND FOR THE RATIFICATION IN NUMBER 2.

1. ELECTION OF DIRECTORS OF THE COMPANY. (INSTRUCTION: TO
WITHHOLD AUTHORITY TO VOTE FOR ANY INDIVIDUAL NOMINEE,
STRIKE A LINE THROUGH, OR OTHERWISE STRIKE, THAT NOMINEE'S
NAME IN THE LIST BELOW.)

[ ] FOR ALL NOMINEES LISTED [ ] WITHHOLD AUTHORITY TO
BELOW EXCEPT AS MARKED VOTE FOR ALL NOMINEES
TO THE CONTRARY. BELOW.

DAVID P. SUMMERS M. DWIGHT CANTRELL
GARY R. BALL

2. PROPOSAL TO RATIFY THE SELECTION OF HAM, LANGSTON AND
BREZINA, L.L.P. AS THE COMPANY'S INDEPENDENT AUDITOR FOR THE FISCAL
YEAR ENDING JUNE 30, 2003.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

3. IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE
UPON SUCH OTHER BUSINESS THAT MAY PROPERLY COME
BEFORE THE ANNUAL MEETING.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

Please sign exactly as name appears below. When shares are held by joint
tenants, both should sign. When signing as attorney, as executor, administrator,
trustee or guardian, please give full title as such. If a corporation, please
sign in full corporate name by President or other authorized officer. If a
partnership, please sign in partnership name by authorized person.

NUMBER OF SHARES OWNED
------------

IF HELD JOINTLY:
SIGNATURE SIGNATURE
-------------------------- --------------------------
(TYPED (TYPED
OR PRINTED OR PRINTED
NAME) NAME)
------------------------------- -------------------------------

DATED: DATED:
----------------------------- -----------------------------

THIS PROXY MAY BE REVOKED AT ANY TIME BEFORE IT IS VOTED AT THE MEETING.
PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY.